Free tool
Drug Trial Radar: Oncology
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
34
Recruiting, industry sponsors, Oncology, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed335
34 trials
Showing 1 to 25, recently updated first.
- Avapritinib Rollover StudyRecruiting
Blueprint Medicines CorporationIndustry
NCT06748001 · 60 participants (planned) · Start Nov 28, 2024 · Primary completion Dec 31, 2027
Drug: Avapritinib · For: Mastocytosis, Systemic
Sites: Edegem, Belgium; Toronto, Canada; Paris, France · 10 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT03340506 · 100 participants (planned) · Start Jan 26, 2018 · Primary completion Dec 28, 2032
Drug: dabrafenib; trametinib · For: Melanoma; Non Small Cell Lung Cancer; Solid Tumor and 2 more
Sites: Scottsdale, Arizona; Bethesda, Maryland; Columbus, Ohio · 37 sites in all
- Asciminib Roll-over StudyRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04877522 · 347 participants (planned) · Start Aug 30, 2022 · Primary completion Aug 30, 2030
Drug: Asciminib single agent; Imatinib and 4 more · For: Chronic Myelogenous Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Sites: Ann Arbor, Michigan; St Louis, Missouri; New York, New York · 88 sites in all
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyIndustry
NCT07176689 · 50 participants (planned) · Start Sep 17, 2025 · Primary completion Feb 26, 2031
Drug: Nirogacestat · For: Desmoid Tumor; Aggressive Fibromatosis
Sites: Brussels, Belgium; Mannheim, Germany; Meldola, Italy · 23 sites in all
BayerBayer (BAYRY)
NCT05348876 · 50 participants (planned) · Start Aug 3, 2022 · Primary completion Dec 30, 2027
Drug: Darolutamide (Nubeqa, BAY1841788) · For: Non-metastatic Castration-resistant Prostate Cancer
Sites: Nadiād, India; Bengaluru, India; Kochi, India · 15 sites in all
Blue Earth DiagnosticsIndustry
NCT07569926 · 142 participants (planned) · Start Aug 31, 2026 · Primary completion Dec 31, 2027
Drug: fluciclovine (18F) · For: Prostate Cancer
Sites: San Diego, California; Atlanta, Georgia; Boston, Massachusetts · 6 sites in all
- Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical CancerRecruiting
PfizerPfizer (PFE)
NCT06952660 · 100 participants (planned) · Start May 7, 2025 · Primary completion Dec 13, 2028
Drug: TIVDAK · For: Cervical Cancer
Sites: Phoenix, Arizona; Scottsdale, Arizona; Tempe, Arizona · 135 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT07218341 · 150 participants (planned) · Start Mar 9, 2026 · Primary completion May 2030
Drug: Pirtobrutinib; Idelalisib · For: Chronic Lymphocytic Leukemia; Lymphoma, Small Lymphocytic
Sites: Mobile, Alabama; Tucson, Arizona; Jacksonville, Florida · 50 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05201781 · 295 participants (planned) · Start Mar 9, 2022 · Primary completion Jul 29, 2037
Drug: Cilta-cel · For: Multiple Myeloma
Sites: Phoenix, Arizona; Duarte, California; San Francisco, California · 50 sites in all
- Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's SyndromeRecruiting
RECORDATI GROUPIndustry
NCT07247162 · 63 participants (planned) · Start Aug 26, 2026 · Primary completion May 2028
Drug: Osilodrostat; Placebo · For: Hypertension; Hypercortisolemia; Cushing Syndrome
Sites: Jacksonville, Florida; Canton, Ohio; Weslaco, Texas
AstraZenecaAstraZeneca (AZN)
NCT07357597 · 100 participants (planned) · Start Jun 24, 2026 · Primary completion Jan 4, 2028
Drug: Dexamethasone mouthwash; Datopotamab Deruxtecan (Dato-DXd) · For: Stomatitis
Sites: Tucson, Arizona; Hot Springs, Arkansas; Little Rock, Arkansas · 41 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07609940 · 30 participants (planned) · Start Jul 15, 2026 · Primary completion Oct 11, 2027
Drug: Linvoseltamab; Tocilizumab · For: Relapsed/Refractory Multiple Myeloma (RRMM)
Sites: Los Angeles, California; St. Petersburg, Florida; Baton Rouge, Louisiana · 7 sites in all
PfizerPfizer (PFE)
NCT05203172 · 210 participants (planned) · Start Jul 5, 2022 · Primary completion Jul 31, 2029
Drug: Binimetinib; Encorafenib and 11 more · For: Solid Tumors
Sites: Phoenix, Arizona; Atlanta, Georgia; Boston, Massachusetts · 77 sites in all
AstraZenecaAstraZeneca (AZN)
NCT07279935 · 100 participants (planned) · Start May 26, 2026 · Primary completion May 18, 2030
Drug: Osimertinib+cisplatin or carboplatin + pemetrexed Edit · For: Non-small Cell Lung Cancer
Sites: Beijing, China; Chengdu, China; Chongqing, China · 32 sites in all
AstraZenecaAstraZeneca (AZN)
NCT06651970 · 60 participants (planned) · Start Feb 4, 2025 · Primary completion Sep 30, 2032
Drug: Acalabrutinib · For: Chronic Lymphocytic Leukaemia; Moderate to Severe Cardiac Impairment
Sites: Charlotte, North Carolina; Columbus, Ohio; Philadelphia, Pennsylvania · 23 sites in all
AbbVieAbbVie (ABBV)
NCT07044687 · 100 participants (planned) · Start Jul 24, 2025 · Primary completion Nov 2027
Drug: Venetoclax; Azacitidine and 1 more · For: Acute Myeloid Leukemia
Sites: Gurgaon, India; Bengaluru, India; Thiruvananthapuram, India · 14 sites in all
- Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of WartsPivotal-lookingRecruiting
Labo'LifeIndustry
NCT03977753 · 162 participants (planned) · Start Feb 17, 2020 · Primary completion Dec 16, 2028
Drug: 2LVERU® or 2LVERU® JUNIOR; Placebo · For: Common Wart; Flat Wart; Plantar Wart
Sites: Bouge, Belgium; Ghent, Belgium; Oisquercq, Belgium · 6 sites in all
Labo'LifeIndustry
NCT04308278 · 88 participants (planned) · Start Jan 22, 2021 · Primary completion Aug 22, 2028
Drug: 2LEBV® / 2LXFS®; Placebo · For: EBV Infection
Sites: Heule, Belgium; Aartselaar, Belgium; Brussels, Belgium · 8 sites in all
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT06862219 · 100 participants (planned) · Start Jun 21, 2025 · Primary completion Dec 31, 2026
Drug: Enfortumab Vedotin · For: Metastatic Urothelial Carcinoma
Sites: Patna, India; Kochi, India; Mumbai, India · 15 sites in all
Rigel PharmaceuticalsIndustry
NCT07486713 · 16 participants (planned) · Start Feb 23, 2026 · Primary completion Apr 30, 2027
Drug: Olutasidenib; CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates · For: AML (Acute Myeloid Leukemia); Glioma; Cholangiocarcinoma and 1 more
Sites: Orange, California; New York, New York
Rigel PharmaceuticalsIndustry
NCT07704658 · 12 participants (planned) · Start Mar 4, 2026 · Primary completion Jul 30, 2027
Drug: Pralsetinib; CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive · For: NSCLC (Non-small Cell Lung Cancer); Thyroid Cancer; Solid Tumor Malignancies and 1 more
Sites: Logroño, Spain; Madrid, Spain
Coherus Oncology, Inc.Industry
NCT06457503 · 100 participants (planned) · Start Nov 1, 2024 · Primary completion Dec 2027
Drug: Toripalimab; Cisplatin and 2 more · For: Nasopharyngeal Cancer Recurrent
Sites: Little Rock, Arkansas; Irvine, California; San Francisco, California · 13 sites in all
TakedaTakeda (TAK)
NCT06562543 · 78 participants (planned) · Start Jan 14, 2025 · Primary completion Oct 4, 2027
Drug: Fruquintinib · For: Colorectal Cancer
Sites: Birmingham, Alabama; Chandler, Arizona; Tucson, Arizona · 45 sites in all
PfizerPfizer (PFE)
NCT06057402 · 80 participants (planned) · Start Oct 3, 2023 · Primary completion Feb 22, 2032
Drug: Elranatamab · For: Multiple Myeloma
Sites: Irvine, California; Orange, California; Fort Collins, Colorado · 33 sites in all
- Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate CancerRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05803941 · 700 participants (planned) · Start Aug 14, 2023 · Primary completion Jul 20, 2033
Drug: AAA617 · For: Prostate Cancer
Sites: Scottsdale, Arizona; Orange, California; Santa Monica, California · 54 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.